Algiax 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
laflunimus (AP-325) / Algiax
NCT05160272: Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients With Type 2 Diabetes

Recruiting
2
38
Europe
AP-325, Placebo matching AP-325
The Deutsche Diabetes Forschungsgesellschaft e.V., Algiax Pharmaceuticals GmbH
Type2 Diabetes
01/25
06/25
NCT04429919 / 2019-003502-28: AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

Completed
2
99
Europe, RoW
AP-325, Placebo
Algiax Pharmaceuticals GmbH, FGK Clinical Research GmbH
Peripheral Post-surgical Neuropathic Pain
10/24
10/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
laflunimus (AP-325) / Algiax
NCT05160272: Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients With Type 2 Diabetes

Recruiting
2
38
Europe
AP-325, Placebo matching AP-325
The Deutsche Diabetes Forschungsgesellschaft e.V., Algiax Pharmaceuticals GmbH
Type2 Diabetes
01/25
06/25
NCT04429919 / 2019-003502-28: AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

Completed
2
99
Europe, RoW
AP-325, Placebo
Algiax Pharmaceuticals GmbH, FGK Clinical Research GmbH
Peripheral Post-surgical Neuropathic Pain
10/24
10/24

Download Options